earningsconfidence high
Fractyl Health Q1 net income $9.2M on non-cash warrant change; Revita pivotal data on track for early Q4
FRACTYL HEALTH, INC.
2026-Q1 EPS
reported $0.06
vs consensus -$0.16
▲ beat
(+136.8%)
- Q1 R&D expenses $15.6M (down from $19.4M YoY); SG&A $5.2M; adjusted EBITDA -$18.0M.
- Cash $63.2M; runway into early 2027, beyond anticipated pivotal data readout.
- Revita REMAIN-1 Pivotal topline 6-month data expected early Q4 2026; FDA De Novo submission target late Q4 2026.
- 1-year REVEAL-1 Cohort data in Q2 2026; 1-year randomized REMAIN-1 Midpoint data in Q3 2026.
- RJVA-001 first-in-human dosing and preliminary data expected in H2 2026 after Netherlands CTA authorization.
item 2.02item 9.01
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.